NEWS AceLink Therapeutics Announced the establishment of AceLink Therapeutics (SuZhou) Co. Ltd. Newark, CA and SuZhou, China, August 10, 2021 AceLink Therapeutics Inc., a clinical stage biopharmaceutical company developing transformative therapies for kidney diseases, announced today that it has established AceLink Therapeutics China subsidiary at Suzhou Industry Park, China. Dr. Jerry Shen, Chairman, CEO and… Continue reading AceLink Therapeutics Announced the establishment of AceLink Therapeutics (SuZhou) Co. Ltd.
Month: March 2022
AceLink Therapeutics Announced Dosing First Human Subject in a Phase I Clinical Trial with its GCS inhibitor AL01211
NEWS AceLink Therapeutics Announced Dosing First Human Subject in a Phase I Clinical Trial with its GCS inhibitor AL01211 Newark, CA, July 6, 2021 AceLink Therapeutics, Inc. (AceLink), an innovative biopharmaceutical company developing transformative therapies for kidney diseases, today announced dosing the first human subject in its Phase I clinical trial evaluating AL01211, a novel… Continue reading AceLink Therapeutics Announced Dosing First Human Subject in a Phase I Clinical Trial with its GCS inhibitor AL01211